The Henry Ford Health System is an organization of six hospitals, nine emergency rooms, 40 general medical centers, and seven specialized medical facilities. It is a major provider of health care in the Detroit Metro area. The Detroit News reports on a study in the system that is sure to cause some controversy:
A Henry Ford Health System study shows the controversial anti-malaria drug hydroxychloroquine helps lower the death rate of COVID-19 patients, the Detroit-based health system said Thursday.
Officials with the Michigan health system said the study found the drug “significantly†decreased the death rate of patients involved in the analysis.
The study analyzed 2,541 patients hospitalized among the system’s six hospitals between March 10 and May 2 and found 13% of those treated with hydroxychloroquine died while 26% of those who did not receive the drug died.
Among all patients in the study, there was an overall in-hospital mortality rate of 18%, and many who died had underlying conditions that put them at greater risk, according to Henry Ford Health System. Globally, the mortality rate for hospitalized patients is between 10% and 30%, and it’s 58% among those in the intensive care unit or on a ventilator.
“As doctors and scientists, we look to the data for insight,†said Steven Kalkanis, CEO of the Henry Ford Medical Group. “And the data here is clear that there was a benefit to using the drug as a treatment for sick, hospitalized patients.â€
Could the difference between this finding and those of other studies that found no benefit be the race of those being treated? Or could it be due to the timing of receiving the drug?
Patients with a median age of 64 were among those analyzed, with 51% men and 56% African American. Roughly 82% of the patients began receiving hydroxychloroquine within 24 hours and 91% within 48 hours, a factor Dr. Marcus Zervos identified as a potential key to the medication’s success.
As noted above this finding is sure to provoke comment, given the other studies finding the opposite and the politicization of the drug.






